For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

Concerns Rise Over Black Market for Unapproved Obesity Drug Retatrutide

Aug 31, 2026
Concerns Rise Over Black Market for Unapproved Obesity Drug Retatrutide

The rise in popularity of weight-loss drugs, particularly GLP-1 receptor agonists, has coincided with the emergence of a black market for the unapproved obesity drug retatrutide. This situation has raised alarms among public health experts across the United States. According to reports, a black market version of retatrutide has infiltrated health spas and social media marketplaces, despite the drug not yet being submitted for FDA review, let alone receiving approval. Developed by Eli Lilly, retatrutide functions as a triple-hormone-receptor agonist, activating GLP-1 along with two other proteins, GIP and glucagon receptors, to help reduce appetite, control insulin levels, and increase calorie expenditure. Early trials suggest promising results, with reports of an average weight loss of 71.2 pounds. However, statements from Eli Lilly's investors should be approached with caution, particularly given the for-profit nature of the pharmaceutical industry. Currently, Eli Lilly does not plan to submit its application for FDA approval until 2027, rendering any available versions of retatrutide highly questionable. Medical researchers may theoretically source retatrutide from lab supply companies, but no authorized provider in the U.S. is permitted to prescribe it for weight loss. The risks associated with using black market versions are significant. A recent report by ABC Australia highlighted a case where a counterfeit vial of retatrutide resulted in severe liver injury for a patient, potentially due to a contaminated batch. As clinical trials for retatrutide are still in their infancy, health authorities cannot confirm the exact cause of these adverse effects. Marie Sinclair, a liver transplant specialist, noted that users of unregulated peptides may experience severe symptoms, including jaundice, which can be alarming and indicative of serious health issues. In response to the proliferation of black market drugs, Eli Lilly has initiated legal action against various med spas and pharmacies involved in selling unauthorized versions of retatrutide. John Hertig, a pharmaceutical practice lecturer, emphasized the importance of evidence-based medicine, stating that excitement for new therapies should not outpace the necessary scientific validation to ensure safety and efficacy. He stressed that patients deserve treatments backed by rigorous evidence rather than unauthorized products marketed prematurely.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)